# Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

> **NCT07117890** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 34 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** sunvozertinib 300mg
- **DRUG:** sunvozertinib 200mg

## Key facts

- **NCT ID:** NCT07117890
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-07
- **Primary completion:** 2027-02-20
- **Final completion:** 2027-05-30
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07117890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07117890, "Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07117890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*